ALEXANDRIA, Va., June 4 -- United States Patent no. 12,318,396, issued on June 3.
"Oral (17-Beta)-3-oxoandrost-4-en-17-yl tridecanoate therapy" was invented by Kilyoung Kim (Salt Lake City), Mahesh V. Patel (Salt Lake City) and Nachiappan Chidambaram (Salt Lake City).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-Beta)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17Beta-ol-3-one esters that comprise (17-Beta)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-Beta)-3-oxoandrost-4-en-17-yl undecanoa...